CO5700764A2 - Dihidroquinazolinas sustituidas con propiedades antivirales - Google Patents

Dihidroquinazolinas sustituidas con propiedades antivirales

Info

Publication number
CO5700764A2
CO5700764A2 CO05111848A CO05111848A CO5700764A2 CO 5700764 A2 CO5700764 A2 CO 5700764A2 CO 05111848 A CO05111848 A CO 05111848A CO 05111848 A CO05111848 A CO 05111848A CO 5700764 A2 CO5700764 A2 CO 5700764A2
Authority
CO
Colombia
Prior art keywords
alkyl
halogen
cyano
nitro
alkoxy
Prior art date
Application number
CO05111848A
Other languages
English (en)
Spanish (es)
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Jurgen Reefschlager
Rudolf Schohe-Loop
Frank Sussmeier
Holger Zimmermann
Rolf Grosser
Kerstin Henninger
Guy Hewlett
Jorg Keldenich
Dieter Lang
Peter Nell
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700764(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CO5700764A2 publication Critical patent/CO5700764A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO05111848A 2003-05-02 2005-11-02 Dihidroquinazolinas sustituidas con propiedades antivirales CO5700764A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline

Publications (1)

Publication Number Publication Date
CO5700764A2 true CO5700764A2 (es) 2006-11-30

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05111848A CO5700764A2 (es) 2003-05-02 2005-11-02 Dihidroquinazolinas sustituidas con propiedades antivirales

Country Status (38)

Country Link
US (4) US7196086B2 (enExample)
EP (1) EP1622880B3 (enExample)
JP (1) JP4733631B2 (enExample)
KR (1) KR100927063B1 (enExample)
CN (1) CN100393706C (enExample)
AR (1) AR044078A1 (enExample)
AT (1) ATE355280T1 (enExample)
AU (1) AU2004233978B2 (enExample)
BR (1) BRPI0410029B8 (enExample)
CA (1) CA2524069C (enExample)
CL (1) CL2004000930A1 (enExample)
CO (1) CO5700764A2 (enExample)
CY (2) CY1106476T1 (enExample)
DE (2) DE10319612A1 (enExample)
DK (1) DK1622880T6 (enExample)
EC (1) ECSP056138A (enExample)
EG (1) EG25273A (enExample)
ES (1) ES2284007T7 (enExample)
FR (1) FR18C1029I2 (enExample)
HN (1) HN2004000146A (enExample)
HU (2) HUS1800018I1 (enExample)
IL (1) IL171513A (enExample)
MA (1) MA27794A1 (enExample)
MX (1) MXPA05011707A (enExample)
MY (1) MY144616A (enExample)
NL (1) NL300933I2 (enExample)
NO (2) NO333265B3 (enExample)
NZ (1) NZ543317A (enExample)
PE (1) PE20050145A1 (enExample)
PL (1) PL1622880T6 (enExample)
PT (1) PT1622880E (enExample)
RU (1) RU2360912C2 (enExample)
SI (1) SI1622880T1 (enExample)
TW (1) TWI335912B (enExample)
UA (1) UA82519C2 (enExample)
UY (1) UY28294A1 (enExample)
WO (1) WO2004096778A1 (enExample)
ZA (1) ZA200508710B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
SMT201900327T1 (it) * 2013-06-19 2019-07-11 Aicuris Anti Infective Cures Gmbh Letermovir amorfo e formulazioni farmaceutiche solide per somministrazione orale dello stesso
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
US10392353B2 (en) * 2015-11-24 2019-08-27 Merck Sharp & Dohme Corp. Processes for making substituted quinazoline compounds using hydrogen bonding catalysts
ES2882531T3 (es) 2016-08-08 2021-12-02 Phaeno Therapeutics Co Ltd Compuesto anti-virus CMVH
EP3753942B1 (en) * 2018-02-08 2024-01-03 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
CA3155287A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
AR121439A1 (es) * 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39097A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39098A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
WO2022038457A1 (en) 2020-08-17 2022-02-24 Lupin Limited A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
UY40078A (es) * 2021-12-21 2023-06-30 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE60113865T2 (de) * 2000-07-31 2006-07-20 Vernalis Research Ltd., Winnersh Piperazin derivate
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
ES2252455T3 (es) 2001-04-19 2006-05-16 Bayer Healthcare Ag Arilsulfonamidas como agentes antivirales.
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) * 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 T-형 칼슘 채널 차단제로서 유용한 3,4-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
KR20080009048A (ko) * 2005-01-25 2008-01-24 프롤렉시스 파마슈티칼스, 인크. 항종양제로서 퀴녹살린 유도체
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ATE449097T1 (de) * 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
SMT201900327T1 (it) * 2013-06-19 2019-07-11 Aicuris Anti Infective Cures Gmbh Letermovir amorfo e formulazioni farmaceutiche solide per somministrazione orale dello stesso

Also Published As

Publication number Publication date
JP4733631B2 (ja) 2011-07-27
CA2524069A1 (en) 2004-11-11
NZ543317A (en) 2008-05-30
BRPI0410029B1 (pt) 2019-12-31
BRPI0410029A (pt) 2006-04-25
TW200510343A (en) 2005-03-16
ES2284007T3 (es) 2007-11-01
DK1622880T3 (da) 2007-06-25
CN100393706C (zh) 2008-06-11
RU2360912C2 (ru) 2009-07-10
US20070191387A1 (en) 2007-08-16
MA27794A1 (fr) 2006-03-01
IL171513A (en) 2011-11-30
NO333265B1 (no) 2013-04-22
CY2018019I2 (el) 2018-12-12
AR044078A1 (es) 2005-08-24
EP1622880A1 (de) 2006-02-08
DE10319612A1 (de) 2004-11-18
CL2004000930A1 (es) 2005-03-18
KR100927063B1 (ko) 2009-11-13
FR18C1029I1 (enExample) 2018-08-17
CY1106476T1 (el) 2012-01-25
FR18C1029I2 (fr) 2020-07-17
NO333265B3 (no) 2019-06-03
USRE46791E1 (en) 2018-04-17
NO2018022I1 (no) 2018-07-04
USRE49698E1 (en) 2023-10-17
MXPA05011707A (es) 2006-02-13
EP1622880B1 (de) 2007-02-28
US8513255B2 (en) 2013-08-20
WO2004096778A1 (de) 2004-11-11
HN2004000146A (es) 2008-06-24
DE502004003052D1 (de) 2007-04-12
PL1622880T6 (pl) 2018-08-31
DK1622880T6 (da) 2018-06-18
NO20055649L (no) 2006-01-31
UA82519C2 (uk) 2008-04-25
HUS1800028I1 (hu) 2018-07-30
HK1092463A1 (zh) 2007-02-09
SI1622880T1 (sl) 2007-08-31
BRPI0410029B8 (pt) 2021-06-15
KR20060009883A (ko) 2006-02-01
ES2284007T7 (es) 2018-06-20
AU2004233978A1 (en) 2004-11-11
CY2018019I1 (el) 2018-12-12
HUS1800018I1 (hu) 2018-05-28
CN1784390A (zh) 2006-06-07
NL300933I2 (nl) 2018-04-26
RU2005137276A (ru) 2006-07-27
EP1622880B3 (de) 2018-05-23
US20050065160A1 (en) 2005-03-24
TWI335912B (en) 2011-01-11
MY144616A (en) 2011-10-14
ECSP056138A (es) 2006-04-19
AU2004233978B2 (en) 2010-02-11
UY28294A1 (es) 2004-11-30
PL1622880T3 (pl) 2007-08-31
ZA200508710B (en) 2006-12-27
NO20055649D0 (no) 2005-11-30
ATE355280T1 (de) 2006-03-15
JP2006525249A (ja) 2006-11-09
EG25273A (en) 2011-12-04
CA2524069C (en) 2011-11-08
PE20050145A1 (es) 2005-05-22
PT1622880E (pt) 2007-06-04
US7196086B2 (en) 2007-03-27

Similar Documents

Publication Publication Date Title
CO5700764A2 (es) Dihidroquinazolinas sustituidas con propiedades antivirales
ES2607952T3 (es) Derivados tricíclicos de Pirazol Amina
AR055071A1 (es) Derivados de pirrolo (3,2 - b) pirimidina. composiciones farmaceuticas.
AR058776A1 (es) Compuesto de piridina condensado
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
DOP2005000123A (es) Inhibidores de cetp
DOP2012000318A (es) Compuestos heterociclicos fusionados
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR114354A2 (es) Derivados de pirimidina
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR055144A1 (es) Inhibidor de secrecion acida
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
CO6251247A2 (es) Imidazoquinolinas con propiedades inmuno-moduladoras
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
CO6351693A2 (es) Nuevos derivados de acilamonobenzamida
PA8654501A1 (es) Derivados de quinazolina inhibidores de quinasas dirigidos a multiples blancos
AR060810A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
AR066603A1 (es) Derivados de arilamida pirimidona

Legal Events

Date Code Title Description
FG Application granted